The investigational therapy LYT-100 (deupirfenidone) significantly slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF), outperforming the standard of care therapy Esbriet.
The holidays have arrived, which reminds of those passenger-side mirrors that read, “Objects in mirror are closer than they appear.” It wasn’t too long ago that the holidays seemed far away, yet here ...